Pazdur mounts defense of accelerated approval during Cures 2.0 panel
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/PolicyRegulatory NewsMichael MezherBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/Policy